Copyright Reports & Markets. All rights reserved.

Global Hepatic Encephalopathy (HE) Therapeutics Market Professional Survey Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Industry Overview of Hepatic Encephalopathy (HE) Therapeutics

      • 1.1 Definition of Hepatic Encephalopathy (HE) Therapeutics
      • 1.2 Hepatic Encephalopathy (HE) Therapeutics Segment by Type
        • 1.2.1 Global Hepatic Encephalopathy (HE) Therapeutics Production Growth Rate Comparison by Types (2014-2025)
        • 1.2.2 Lactulose
        • 1.2.3 Rifaximin
        • 1.2.4 Neomycin
        • 1.2.5 Probiotics
        • 1.2.6 Thiamine
      • 1.3 Hepatic Encephalopathy (HE) Therapeutics Segment by Applications
        • 1.3.1 Global Hepatic Encephalopathy (HE) Therapeutics Consumption Comparison by Applications (2014-2025)
        • 1.3.2 Acute Liver Failure
        • 1.3.3 Portal Systemic Bypass Without Liver Disease
        • 1.3.4 Liver Cirrhosis
      • 1.4 Global Hepatic Encephalopathy (HE) Therapeutics Overall Market
        • 1.4.1 Global Hepatic Encephalopathy (HE) Therapeutics Revenue (2014-2025)
        • 1.4.2 Global Hepatic Encephalopathy (HE) Therapeutics Production (2014-2025)
        • 1.4.3 North America Hepatic Encephalopathy (HE) Therapeutics Status and Prospect (2014-2025)
        • 1.4.4 Europe Hepatic Encephalopathy (HE) Therapeutics Status and Prospect (2014-2025)
        • 1.4.5 China Hepatic Encephalopathy (HE) Therapeutics Status and Prospect (2014-2025)
        • 1.4.6 Japan Hepatic Encephalopathy (HE) Therapeutics Status and Prospect (2014-2025)
        • 1.4.7 Southeast Asia Hepatic Encephalopathy (HE) Therapeutics Status and Prospect (2014-2025)
        • 1.4.8 India Hepatic Encephalopathy (HE) Therapeutics Status and Prospect (2014-2025)

      2 Manufacturing Cost Structure Analysis

      • 2.1 Raw Material and Suppliers
      • 2.2 Manufacturing Cost Structure Analysis of Hepatic Encephalopathy (HE) Therapeutics
      • 2.3 Manufacturing Process Analysis of Hepatic Encephalopathy (HE) Therapeutics
      • 2.4 Industry Chain Structure of Hepatic Encephalopathy (HE) Therapeutics

      3 Development and Manufacturing Plants Analysis of Hepatic Encephalopathy (HE) Therapeutics

      • 3.1 Capacity and Commercial Production Date
      • 3.2 Global Hepatic Encephalopathy (HE) Therapeutics Manufacturing Plants Distribution
      • 3.3 Major Manufacturers Technology Source and Market Position of Hepatic Encephalopathy (HE) Therapeutics
      • 3.4 Recent Development and Expansion Plans

      4 Key Figures of Major Manufacturers

      • 4.1 Hepatic Encephalopathy (HE) Therapeutics Production and Capacity Analysis
      • 4.2 Hepatic Encephalopathy (HE) Therapeutics Revenue Analysis
      • 4.3 Hepatic Encephalopathy (HE) Therapeutics Price Analysis
      • 4.4 Market Concentration Degree

      5 Hepatic Encephalopathy (HE) Therapeutics Regional Market Analysis

      • 5.1 Hepatic Encephalopathy (HE) Therapeutics Production by Regions
        • 5.1.1 Global Hepatic Encephalopathy (HE) Therapeutics Production by Regions
        • 5.1.2 Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Regions
      • 5.2 Hepatic Encephalopathy (HE) Therapeutics Consumption by Regions
      • 5.3 North America Hepatic Encephalopathy (HE) Therapeutics Market Analysis
        • 5.3.1 North America Hepatic Encephalopathy (HE) Therapeutics Production
        • 5.3.2 North America Hepatic Encephalopathy (HE) Therapeutics Revenue
        • 5.3.3 Key Manufacturers in North America
        • 5.3.4 North America Hepatic Encephalopathy (HE) Therapeutics Import and Export
      • 5.4 Europe Hepatic Encephalopathy (HE) Therapeutics Market Analysis
        • 5.4.1 Europe Hepatic Encephalopathy (HE) Therapeutics Production
        • 5.4.2 Europe Hepatic Encephalopathy (HE) Therapeutics Revenue
        • 5.4.3 Key Manufacturers in Europe
        • 5.4.4 Europe Hepatic Encephalopathy (HE) Therapeutics Import and Export
      • 5.5 China Hepatic Encephalopathy (HE) Therapeutics Market Analysis
        • 5.5.1 China Hepatic Encephalopathy (HE) Therapeutics Production
        • 5.5.2 China Hepatic Encephalopathy (HE) Therapeutics Revenue
        • 5.5.3 Key Manufacturers in China
        • 5.5.4 China Hepatic Encephalopathy (HE) Therapeutics Import and Export
      • 5.6 Japan Hepatic Encephalopathy (HE) Therapeutics Market Analysis
        • 5.6.1 Japan Hepatic Encephalopathy (HE) Therapeutics Production
        • 5.6.2 Japan Hepatic Encephalopathy (HE) Therapeutics Revenue
        • 5.6.3 Key Manufacturers in Japan
        • 5.6.4 Japan Hepatic Encephalopathy (HE) Therapeutics Import and Export
      • 5.7 Southeast Asia Hepatic Encephalopathy (HE) Therapeutics Market Analysis
        • 5.7.1 Southeast Asia Hepatic Encephalopathy (HE) Therapeutics Production
        • 5.7.2 Southeast Asia Hepatic Encephalopathy (HE) Therapeutics Revenue
        • 5.7.3 Key Manufacturers in Southeast Asia
        • 5.7.4 Southeast Asia Hepatic Encephalopathy (HE) Therapeutics Import and Export
      • 5.8 India Hepatic Encephalopathy (HE) Therapeutics Market Analysis
        • 5.8.1 India Hepatic Encephalopathy (HE) Therapeutics Production
        • 5.8.2 India Hepatic Encephalopathy (HE) Therapeutics Revenue
        • 5.8.3 Key Manufacturers in India
        • 5.8.4 India Hepatic Encephalopathy (HE) Therapeutics Import and Export

      6 Hepatic Encephalopathy (HE) Therapeutics Segment Market Analysis (by Type)

      • 6.1 Global Hepatic Encephalopathy (HE) Therapeutics Production by Type
      • 6.2 Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Type
      • 6.3 Hepatic Encephalopathy (HE) Therapeutics Price by Type

      7 Hepatic Encephalopathy (HE) Therapeutics Segment Market Analysis (by Application)

      • 7.1 Global Hepatic Encephalopathy (HE) Therapeutics Consumption by Application
      • 7.2 Global Hepatic Encephalopathy (HE) Therapeutics Consumption Market Share by Application (2014-2019)

      8 Hepatic Encephalopathy (HE) Therapeutics Major Manufacturers Analysis

      • 8.1 ASKA Pharmaceutical
        • 8.1.1 ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Production Sites and Area Served
        • 8.1.2 ASKA Pharmaceutical Product Introduction, Application and Specification
        • 8.1.3 ASKA Pharmaceutical Hepatic Encephalopathy (HE) Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.1.4 Main Business and Markets Served
      • 8.2 COSMO PHARMACEUTICALS
        • 8.2.1 COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Production Sites and Area Served
        • 8.2.2 COSMO PHARMACEUTICALS Product Introduction, Application and Specification
        • 8.2.3 COSMO PHARMACEUTICALS Hepatic Encephalopathy (HE) Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.2.4 Main Business and Markets Served
      • 8.3 Mallinckrodt
        • 8.3.1 Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Production Sites and Area Served
        • 8.3.2 Mallinckrodt Product Introduction, Application and Specification
        • 8.3.3 Mallinckrodt Hepatic Encephalopathy (HE) Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.3.4 Main Business and Markets Served
      • 8.4 Valeant
        • 8.4.1 Valeant Hepatic Encephalopathy (HE) Therapeutics Production Sites and Area Served
        • 8.4.2 Valeant Product Introduction, Application and Specification
        • 8.4.3 Valeant Hepatic Encephalopathy (HE) Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.4.4 Main Business and Markets Served

      9 Development Trend of Analysis of Hepatic Encephalopathy (HE) Therapeutics Market

      • 9.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Trend Analysis
        • 9.1.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size (Volume and Value) Forecast 2019-2025
      • 9.2 Hepatic Encephalopathy (HE) Therapeutics Regional Market Trend
        • 9.2.1 North America Hepatic Encephalopathy (HE) Therapeutics Forecast 2019-2025
        • 9.2.2 Europe Hepatic Encephalopathy (HE) Therapeutics Forecast 2019-2025
        • 9.2.3 China Hepatic Encephalopathy (HE) Therapeutics Forecast 2019-2025
        • 9.2.4 Japan Hepatic Encephalopathy (HE) Therapeutics Forecast 2019-2025
        • 9.2.5 Southeast Asia Hepatic Encephalopathy (HE) Therapeutics Forecast 2019-2025
        • 9.2.6 India Hepatic Encephalopathy (HE) Therapeutics Forecast 2019-2025
      • 9.3 Hepatic Encephalopathy (HE) Therapeutics Market Trend (Product Type)
      • 9.4 Hepatic Encephalopathy (HE) Therapeutics Market Trend (Application)
      • 10.1 Marketing Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
      • 10.3 Hepatic Encephalopathy (HE) Therapeutics Customers

      11 Market Dynamics

      • 11.1 Market Trends
      • 11.2 Opportunities
      • 11.3 Market Drivers
      • 11.4 Challenges
      • 11.5 Influence Factors

      12 Conclusion

        13 Appendix

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        HE is a potentially fatal brain disorder that is caused by liver damage, which results in the failure to remove toxins from the blood.
        The availability of patient-focused programs to assist disease management is one of the primary growth drivers for the global hepatic encephalopathy (HE) therapeutics market till 2023. Such programs increase the adherence to therapeutics by improving convenience for patients. Norgine collaborated with the European liver patients association (ELPA) to launch Time to DeLiver program, which is focused on changing the perception about HE among all stakeholders, healthcare professionals, and policymakers. This in turn, drives the demand for diagnosis and management of HE.
        The most commonly used therapeutics to treat HE are lactulose and rifaximin. Researchers are also developing treatments that targets ammonia production and removal. For instance, AST-120 is under investigation and targets gut-derived toxins for liver cirrhosis. It can also be used to treat HE. The progression and development of HE sometimes depends on factors such as inflammation. This is compelling researchers to introduce various treatments that targets inflammation. Some of the most recent approaches to treat HE includes probiotics, albumin administration, and dialysis. Such emergence of novel hepatic encephalopathy treatment targets is identified as one of the key trends that will stimulate growth in the hepatic encephalopathy (HE) therapeutics market during the forecasted period.

        The global Hepatic Encephalopathy (HE) Therapeutics market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
        This report focuses on Hepatic Encephalopathy (HE) Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Hepatic Encephalopathy (HE) Therapeutics market size by analyzing historical data and future prospect.
        Regionally, this report categorizes the production, apparent consumption, export and import of Hepatic Encephalopathy (HE) Therapeutics in North America, Europe, China, Japan, Southeast Asia and India.
        For each manufacturer covered, this report analyzes their Hepatic Encephalopathy (HE) Therapeutics manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

        The following manufacturers are covered:
        ASKA Pharmaceutical
        COSMO PHARMACEUTICALS
        Mallinckrodt
        Valeant
        ...

        Segment by Regions
        North America
        Europe
        China
        Japan
        Southeast Asia
        India

        Segment by Type
        Lactulose
        Rifaximin
        Neomycin
        Probiotics
        Thiamine

        Segment by Application
        Acute Liver Failure
        Portal Systemic Bypass Without Liver Disease
        Liver Cirrhosis

        Buy now